华仁药业（300110）8月14日主力资金净流出1233.35万元

Core Viewpoint - Huarun Pharmaceutical's stock has experienced a decline, with significant net outflow of funds and a notable decrease in revenue and profit in the latest financial report [1][3] Financial Performance - As of the first quarter of 2025, Huarun Pharmaceutical reported total revenue of 303 million yuan, a year-on-year decrease of 25.38% [1] - The net profit attributable to shareholders was 16.03 million yuan, down 68.46% year-on-year [1] - The non-recurring net profit was 12.26 million yuan, reflecting a 74.87% decrease compared to the previous year [1] - The company's liquidity ratios are as follows: current ratio at 0.720 and quick ratio at 0.547, with a debt-to-asset ratio of 59.70% [1] Stock Market Activity - Huarun Pharmaceutical's stock closed at 3.49 yuan, down 3.59%, with a turnover rate of 2.5% [1] - The trading volume was 295,000 hands, with a transaction amount of 105 million yuan [1] - There was a net outflow of main funds amounting to 12.33 million yuan, accounting for 11.8% of the transaction amount [1] Company Background - Huarun Pharmaceutical Co., Ltd. was established in 1998 and is located in Qingdao, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.182 billion yuan and a paid-in capital of 100 million yuan [2] - The legal representative of the company is Zhang Li [2] Investment and Intellectual Property - Huarun Pharmaceutical has made investments in 16 enterprises and participated in 1,805 bidding projects [2] - The company holds 64 trademark registrations and 327 patents, along with 117 administrative licenses [2]